瑞康医药集团股份有限公司 2025 年半年度财务报告 2025 年半年度财务报告 2025 年 8 月 1 | | | | 二、财务报表 3 | | --- | | 三、公司基本情况 20 | | 四、财务报表的编制基础 21 | | 五、重要会计政策及会计估计 21 | | 六、税项 45 | | 七、合并财务报表项目注释 46 | | 八、研发支出 94 | | 九、合并范围的变更 95 | | 十、在其他主体中的权益 98 | | 十一、政府补助 109 | | 十二、与金融工具相关的风险 110 | | 十三、公允价值的披露 112 | | 十四、关联方及关联交易 114 | | 十五、股份支付 118 | | 十六、承诺及或有事项 119 | | 十七、资产负债表日后事项 119 | | 十八、其他重要事项 120 | | 十九、母公司财务报表主要项目注释 121 | | 二十、补充资料 138 | | 二十一、财务报表之批准 139 | 瑞康医药集团股份有限公司 2025 年半年度财务报告 一、审计报告 半年度报告是否经过审计 □是 否 公司半年度财务报告未经审计。 二、财务报表 财务附注中报表的 ...

瑞康医药集团股份有限公司 2025 年半年度非经营性资金占用及其他关联资金往来情况汇总表 编制单位：瑞康医药集团股份有限公司 单位：万元 | 资金往来方名称 | 往来方与上 市公司的关 | 上市公司核 算的会计科 | 2025 年期初 往来资金余 | 2025 年半年 度往来累计 | 2025 年半 年度往来 | 2025 年半 年度偿还 | 2025 年半年 度末往来资 | 往来 形成 | 往来性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 联关系 | 目 | 额 | 发生金额 (不含利息) | 资金的利 息(如有) | 累计发生 金额 | 金余额 | 原因 | | | 烟台龙慧康母婴护理有 限公司 | 子公司 | 其他应收款 | 1,102.49 | 505.09 | | 502.67 | 1,104.91 | 借款 | 非经营性往来 | | 吉祥火(烟台)医药科技 有限公司 | 子公司 | 其他应收款 | 18,801.23 | 0.00 | | 0.00 | 18,801.23 | 借款 | 非经营性往来 | ...

Financial Performance - The company achieved total revenue of CNY 3.544 billion in the first half of 2025, representing a decrease of 12.11% compared to CNY 4.032 billion in the same period last year[21]. - Net profit attributable to shareholders was CNY 18.17 million, down 32.35% from CNY 31.03 million year-on-year[21]. - Basic earnings per share decreased to CNY 0.0121, down 32.02% from CNY 0.0206 in the same period last year[21]. - The company's operating revenue for the reporting period was ¥3,543,520,195.09, a decrease of 12.11% compared to ¥4,031,665,203.80 in the same period last year[50]. - The net profit for the first half of 2025 was ¥30,605,041.88, compared to ¥35,062,172.36 in the first half of 2024, indicating a decline of 12.4%[159]. - The total profit for the first half of 2025 was -¥15,385,259.89, contrasting with a profit of ¥34,696,237.15 in the first half of 2024[159]. - The company reported a total comprehensive income of ¥30,605,041.88 for the first half of 2025, compared to ¥35,062,172.36 in the first half of 2024[159]. Cash Flow and Liquidity - The company reported a significant increase in net cash flow from operating activities, reaching CNY 67.89 million, a 642.20% increase compared to CNY 9.33 million in the previous year[21]. - Cash generated from operating activities surged by 642.20% to ¥67,886,098.54, compared to ¥9,146,646.10 in the previous year[50]. - The ending cash and cash equivalents balance for the first half of 2025 was CNY 768,510,021.90, slightly down from CNY 772,743,938.26 in the first half of 2024[165]. - The company's cash and cash equivalents decreased to ¥3,921,137,874.33 from ¥4,159,133,062.01, a decline of approximately 5.7%[156]. - The parent company's net cash flow from operating activities improved to CNY 76,961,495.49 in the first half of 2025, compared to a negative CNY 249,033,623.57 in the same period of 2024[167]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 17.29 billion, an increase of 7.80% from CNY 16.01 billion at the end of the previous year[21]. - The company's cash and cash equivalents increased to ¥5,978,903,824, representing 34.58% of total assets, up from 31.08% last year[56]. - Total liabilities reached ¥11,722,710,642.80, up from ¥10,328,782,054.66, reflecting an increase of approximately 13.5%[153]. - Owner's equity decreased to ¥5,565,925,373.74 from ¥5,708,689,893.70, indicating a decline of about 2.5%[153]. - Total current assets amounted to ¥12,337,954,409.82, up from ¥11,083,869,928.27, which is an increase of around 11.3%[151]. Strategic Focus and Development - The company plans to focus on enhancing its logistics and distribution capabilities, particularly in the traditional Chinese medicine sector, to improve operational efficiency[28]. - The company aims to strengthen its market position by optimizing its business structure and increasing investment in high-growth areas[28]. - The company is committed to improving its core competitiveness despite pressures from cost control and healthcare reform policies[29]. - The company is focusing on market expansion and new product development to mitigate the impact of declining revenues in certain regions[66]. - The company is actively pursuing high-end medical device production and innovative Chinese medicine projects, acknowledging the high R&D costs and risks associated with these investments, and will establish dedicated project teams for better management[70]. Research and Development - The company's research and development investment increased by 15.48% to ¥11,198,402.43 from ¥9,697,668.30 year-on-year[50]. - Research and development expenses increased by 60.3% to 3.48 million yuan, indicating a strong focus on innovation[171]. - The company has allocated 1.5 billion for research and development, focusing on enhancing product features and user experience[173]. Market and Product Development - The in-vitro diagnostics (IVD) segment transitioned from a traditional distributor to an integrated service provider, launching several proprietary diagnostic reagents and devices, particularly enhancing capabilities in biochemical diagnostics and precision medicine[34]. - The digital healthcare segment developed a comprehensive health management service targeting chronic diseases, utilizing wearable devices for data collection and analysis to improve users' quality of life[36]. - The company is developing a new traditional Chinese medicine product, FTZ Concentrated Pill, which has entered the clinical phase II trials[42]. - New product launches are expected to contribute an additional 200 million in revenue over the next two quarters, driven by innovative technology advancements[176]. Governance and Compliance - The company has established a comprehensive governance structure and adheres to legal requirements for information disclosure, ensuring transparency and fairness for all shareholders[97]. - The company operates under the assumption of going concern, with no significant doubts about its ability to continue operations for the next 12 months[186]. - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that the financial statements accurately reflect its financial position as of June 30, 2025[188]. Shareholder Relations and Dividends - The company will not distribute cash dividends or issue bonus shares for this reporting period[5]. - The company plans to increase cash dividends in 2025, with a target that cash distributions will not be less than 30% of the net profit attributable to shareholders[76]. - The company has approved a share repurchase plan with a total amount between RMB 100 million and RMB 200 million, aimed at enhancing investment value and supporting employee stock ownership plans[77][78]. Risks and Challenges - The company faces risks related to policy changes, particularly with the expansion of centralized procurement affecting high-margin products like traditional Chinese medicine injections[67]. - The company faces risks related to accounts receivable recovery, particularly due to prolonged payment cycles influenced by DRG/DIP payment reforms and regulatory oversight, and will implement stricter credit management and risk training[69].

Group 1 - The company, Ruikang Pharmaceutical, stated that as of August 10, 2025, the total number of shareholders is 72,251 [2]

Core Viewpoint - Ruikang Pharmaceutical Group Co., Ltd. has received a notice from the Jiyang District Supervisory Committee in Jinan, which has changed the detention measures against its director, board secretary, and vice president Li Zhe to a directive for pending investigation [1] Summary by Relevant Sections - **Company Announcement** - Ruikang Pharmaceutical disclosed that the Jiyang District Supervisory Committee has lifted the detention measures on Li Zhe, changing it to a directive for pending investigation [1] - **Background of Li Zhe** - Li Zhe, born in 1986, holds a master's degree and has previously worked as a financial advisor at Sun Life Financial in Montreal, a fund management specialist at Canadian Imperial Bank of Commerce in Toronto, and an investment banking project manager at Guojin Securities in Shanghai [1]

Group 1 - Ruikang Pharmaceutical's executive Li Zhe has had his detention changed to a notice of investigation, indicating a shift in the investigation phase [1] - The change from detention to a notice of investigation suggests a reduced level of coercion, highlighting the importance of internal control and compliance systems in listed companies [1] Group 2 - Zhixiang Jintai has initiated a Phase III clinical trial for GR1802 injection for allergic rhinitis, following communication with the National Medical Products Administration [2] - GR1802 is slightly behind in clinical progress compared to two other approved drugs targeting the same indication, but successful commercialization could lead to competition with Dupilumab [2] Group 3 - Rongchang Biopharmaceutical's innovative drug RC18 (Taitaxip) for primary Sjögren's syndrome has met its primary endpoint in Phase III clinical trials, marking a potential first in the global market for this indication [3] - If approved, this drug could provide a breakthrough treatment for millions of patients in China and strengthen Rongchang's position in the autoimmune field [3] Group 4 - Hengrui Medicine's SHR-A2102, a targeted antibody-drug conjugate (ADC) for Nectin-4, has received approval for clinical trials in combination with Atezolizumab for recurrent/metastatic head and neck squamous cell carcinoma [4] - There is currently only one similar product on the market, Padcev, which is projected to generate $1.949 billion in sales in 2024, indicating significant market potential for this target [4] Group 5 - BeiGene has launched the first domestic Phase III clinical trial for subcutaneous Tislelizumab, a PD-1 inhibitor, for use in combination with chemotherapy for locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [5] - The subcutaneous formulation is becoming a competitive area for PD-1/PD-L1 inhibitors, with three other subcutaneous PD-1/L1 products already approved globally [5]

Group 1 - Kaizhong Precision plans to invest up to 250 million yuan to establish a subsidiary and build a production base in Thailand, focusing on overseas connector and precision component business [1] - Longbo Technology reported a 60.18% year-on-year increase in net profit for the first half of 2025, with revenue of 122 million yuan, up 18.03% [2] - Dingyang Technology achieved a net profit of 76.88 million yuan in the first half of 2025, a year-on-year increase of 31.54%, with revenue of 279 million yuan, up 24.61% [4] Group 2 - Heng Rui Pharmaceutical received approval for clinical trials of two drugs, SHR-A2102 and Adebeli monoclonal antibody injection [6] - Maolai Optical plans to use up to 100 million yuan of idle funds for entrusted wealth management to improve fund utilization efficiency [8] - Shiji Information signed a major contract with MGM Grand, providing a next-generation cloud-based hotel information management system [7] Group 3 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 4 - Aolaide expects a net profit decrease of 68.41% to 72.77% for the first half of 2025, with revenue projected between 270 million and 290 million yuan [12] - Feilong Co. used 111 million yuan of idle funds for cash management through structured deposit products [13] - Anhui Construction won two major projects with a total investment exceeding 6.6 billion yuan [15] Group 5 - Yunnan Germanium's subsidiary received a government subsidy of 6.8 million yuan related to revenue [9] - Jizhi Co. received a warning letter from the Zhejiang Securities Regulatory Bureau for failing to disclose significant government subsidies [10] - Dongfang Precision reported a net profit of approximately 397 million yuan for the first half of 2025, a year-on-year increase of 142.52% [11] Group 6 - China Medical's subsidiary received approval for the listing of fumaric acid volnora raw materials [20] - Huayuan Vaccine's subsidiary received approval for clinical trials of Hib vaccine [29] - Ganfeng Lithium plans to integrate lithium salt lake projects in Argentina and provide financial support of up to 130 million USD [41]

Market Overview - The pharmaceutical commercial sector experienced a slight decline of 0.01% on August 13, with Huaren Health leading the drop [1] - The Shanghai Composite Index closed at 3683.46, up 0.48%, while the Shenzhen Component Index closed at 11551.36, up 1.76% [1] Stock Performance - Key stocks in the pharmaceutical commercial sector showed varied performance, with the following notable movements: - Seli Medical (603716) rose by 6.55% to a closing price of 31.09, with a trading volume of 556,200 shares and a transaction value of 1.671 billion [1] - Guofa Co. (600538) increased by 1.75% to 6.38, with a trading volume of 129,600 shares [1] - Huaren Health (301408) fell by 1.76% to 15.11, with a trading volume of 179,600 shares and a transaction value of 271 million [2] Capital Flow - The pharmaceutical commercial sector saw a net inflow of 33.73 million from institutional investors, while retail investors experienced a net outflow of 42.05 million [2] - Notable capital flows for specific stocks included: - Seli Medical had a net inflow of 10.9 million from institutional investors, while retail investors saw a net outflow of 2.46 million [3] - Yiyang Pharmaceutical (301015) had a net inflow of 6.29 million from institutional investors, but retail investors faced a net outflow of 31.02 million [3]

登录新浪财经APP 搜索【信披】查看更多考评等级 公司指定的信息披露媒体为《证券时报》、《中国证券报》、《上海证券报》、《证券日报》和巨潮资 讯网(http://www.cninfo.com.cn)，公司所有信息均以在上述指定媒体刊登的信息为准。 敬请广大投资者理性投资，注意投资风险。 特此公告。 瑞康医药集团股份有限公司 证券代码：002589 证券简称：瑞康医药 公告编号：2025-040 瑞康医药集团股份有限公司 关于公司董事、董事会秘书及副总裁解除留置并变更为责令候查的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述或重大遗 漏。 瑞康医药集团股份有限公司（以下简称"公司"）于2025年7月3日披露了《关于公司董事、董事会秘书及 副总裁被采取留置措施的公告》（公告编号：2025-037），公司董事、董事会秘书及副总裁李喆先生被 实施留置措施。 公司于2025年8月12日收到济南市济阳区监察委员会签发的《变更留置通知书》，济南市济阳区监察委 员会已解除对李喆先生的留置措施，变更为责令候查措施。目前公司生产经营情况正常，李喆先生能够 正常履行董事、董事会秘书及副总裁 ...

Group 1: China Unicom - Company revenue exceeded RMB 200 billion in the first half of the year, with a total profit of RMB 17.7 billion, representing a year-on-year increase of 5.2% [1] - Internet communication revenue reached RMB 131.9 billion, while intelligent network revenue amounted to RMB 45.4 billion, accounting for 26% of total revenue [1] - The number of connected users surpassed 1.2 billion, with mobile and broadband users increasing by over 11 million, reaching a total of 480 million [1] Group 2: Kweichow Moutai - The net profit for the first half of the year increased by 8.89%, with favorable factors outweighing unfavorable ones [2] Group 3: Shuanghui Development - The company reported a total meat product export volume of 1.57 million tons, a year-on-year increase of 3.67%, and total revenue of RMB 28.5 billion, up 3.00% [4] - The total profit decreased by 2.36%, while the net profit attributable to shareholders rose by 1.17% due to improved profitability in tax-exempt businesses [4] Group 4: Pengding Holdings - The company achieved a revenue of RMB 16.375 billion, a year-on-year increase of 24.75%, and a net profit of RMB 1.233 billion, up 57.22% [6] - The increase in revenue was attributed to a rise in customer orders [6] Group 5: Jinlongyu - The company reported a net profit increase of 60.07%, with revenue reaching RMB 115.68 billion, up from RMB 109.48 billion [9] - The growth in revenue was driven by increased sales of kitchen foods, feed raw materials, and oil technology products [9] Group 6: Other Companies - Zhenray Technology reported a turnaround in net profit due to significant growth in main business revenue [12] - Zhongke Sanhuan achieved a net profit increase of 160.82%, despite a revenue decline of 11.17% [16]